These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24647496)

  • 21. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development.
    Wu PC; Lin WL; Wu CM; Chi JN; Chien MS; Huang C
    Appl Microbiol Biotechnol; 2012 Sep; 95(6):1501-7. PubMed ID: 22526782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virus-like particles in vaccine development.
    Roldão A; Mellado MC; Castilho LR; Carrondo MJ; Alves PM
    Expert Rev Vaccines; 2010 Oct; 9(10):1149-76. PubMed ID: 20923267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects for prophylactic hepatitis C vaccines based on virus-like particles.
    Beaumont E; Roingeard P
    Hum Vaccin Immunother; 2013 May; 9(5):1112-8. PubMed ID: 23406827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New picornavirus vaccines for hepatitis A, and lessons from the control of poliomyelitis by the prototype picornavirus vaccines.
    Melnick JL
    Prog Med Virol; 1990; 37():47-55. PubMed ID: 2173848
    [No Abstract]   [Full Text] [Related]  

  • 25. [Virus-Like Particles as an Instrument of Vaccine Production].
    Syomin BV; Ilyin YV
    Mol Biol (Mosk); 2019; 53(3):367-379. PubMed ID: 31184601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a putative filovirus vaccine: virus-like particles.
    Martins KA; Warren TK; Bavari S
    Virol Sin; 2013 Apr; 28(2):65-70. PubMed ID: 23385315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virus-like particle-based vaccines against hepatitis C virus infection.
    Bellier B; Klatzmann D
    Expert Rev Vaccines; 2013 Feb; 12(2):143-54. PubMed ID: 23414406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential of plant-made vaccines to fight picornavirus.
    Bolaños-Martínez OC; Rosales-Mendoza S
    Expert Rev Vaccines; 2020 Jul; 19(7):599-610. PubMed ID: 32609047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.
    Kushnir N; Streatfield SJ; Yusibov V
    Vaccine; 2012 Dec; 31(1):58-83. PubMed ID: 23142589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.
    Azevedo MP; Vlasova AN; Saif LJ
    Expert Rev Vaccines; 2013 Feb; 12(2):169-81. PubMed ID: 23414408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioengineering virus-like particles as vaccines.
    Lua LH; Connors NK; Sainsbury F; Chuan YP; Wibowo N; Middelberg AP
    Biotechnol Bioeng; 2014 Mar; 111(3):425-40. PubMed ID: 24347238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.
    Salazar-González JA; Angulo C; Rosales-Mendoza S
    Vaccine; 2015 Jul; 33(31):3650-8. PubMed ID: 26073010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
    Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
    Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
    Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
    Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge.
    Liu Q; Yan K; Feng Y; Huang X; Ku Z; Cai Y; Liu F; Shi J; Huang Z
    Vaccine; 2012 Oct; 30(47):6642-8. PubMed ID: 22959985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A CD8 T-cell epitope variant enhances immune targeting to a recombinant picornavirus vaccine antigen.
    Bell MP; Renner DN; Johnson AJ; Pavelko KD
    Viral Immunol; 2014 Sep; 27(7):361-6. PubMed ID: 25025983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subviral particle as vaccine and vaccine platform.
    Tan M; Jiang X
    Curr Opin Virol; 2014 Jun; 6():24-33. PubMed ID: 24662314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of human rhinovirus immunogenic epitopes for rational vaccine design.
    Stepanova E; Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2019 Sep; 18(9):877-880. PubMed ID: 31416365
    [No Abstract]   [Full Text] [Related]  

  • 40. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.
    Richardson C; Bargatze RF; Goodwin R; Mendelman PM
    Expert Rev Vaccines; 2013 Feb; 12(2):155-67. PubMed ID: 23414407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.